Evidence map›Paper›PMID 22836147›Full record

ReviewExperimental neurology2012

Scar-mediated inhibition and CSPG receptors in the CNS.

Kartavya Sharma, Michael E Selzer, Shuxin Li

Open access · greenAbstract readReview
In one paragraph

Review in Experimental neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 182 citations in OpenAlex.

  1. Review
  2. The role of type I collagen in white matter injury.Anatomical science international · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Chondroitin Sulfate-Coated Heteroduplex-Molecular Spherical Nucleic Acids.Chembiochem : a European journal of chemical biology · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kartavya SharmaDepartment of Neurology, UT Southwestern Medical Center, Dallas, TX 75390-8813, USA.
Michael E Selzer
Shuxin Li
Southwestern Medical Center · USTemple University · US

Funding

Center for experimental neurorehabilitation trainingR24HD050838 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI SELZER, MICHAEL EDGAR · 2005 to 2012
$3.7M
CSPG-induced retrograde cell death and inhibition of regeneration after SCIR01NS092876 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI SELZER, MICHAEL EDGAR · 2016 to 2020
$1.7M
Overcoming glial scar inhibitions on axonal growthR21NS066114 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI LI, SHUXIN · 2010 to 2011
$432k
NICHD NIH HHS R24 HD050838NINDS NIH HHS 1R21NS066114-01A1NINDS NIH HHS R01 NS092876NINDS NIH HHS R21 NS066114
6 · The paper itself

Abstract

Severed axons in adult mammals do not regenerate appreciably after central nervous system (CNS) injury due to developmentally determined reductions in neuron-intrinsic growth capacity and extracellular environment for axon elongation. Chondroitin sulfate proteoglycans (CSPGs), which are generated by reactive scar tissues, are particularly potent contributors to the growth-limiting environment in mature CNS. Thus, surmounting the strong inhibition by CSPG-rich scar is an important therapeutic goal for achieving functional recovery after CNS injuries. As of now, the main in vivo approach to overcoming inhibition by CSPGs is enzymatic digestion with locally applied chondroitinase ABC (ChABC), but several disadvantages may prevent using this bacterial enzyme as a therapeutic option for patients. A better understanding of the molecular mechanisms underlying CSPG action is needed in order to develop more effective therapies to overcome CSPG-mediated inhibition of axon regeneration and/or sprouting. Because of their large size and dense negative charges, CSPGs were thought to act by non-specifically hindering the binding of matrix molecules to their cell surface receptors through steric interactions. Although this may be true, recent studies indicate that two members of the leukocyte common antigen related (LAR) phosphatase subfamily, protein tyrosine phosphatase σ (PTPσ) and LAR, are functional receptors that bind CSPGs with high affinity and mediate CSPG inhibitory effects. CSPGs also may act by binding to two receptors for myelin-associated growth inhibitors, Nogo receptors 1 and 3 (NgR1 and NgR3). If confirmed, it would suggest that CSPGs have multiple mechanisms by which they inhibit axon growth, making them especially potent and difficult therapeutic targets. Identification of CSPG receptors is not only important for understanding the scar-mediated growth suppression, but also for developing novel and selective therapies to promote axon sprouting and/or regeneration after CNS injuries, including spinal cord injury (SCI).

Indexed as

AnimalsChondroitin ABC LyaseChondroitin Sulfate ProteoglycansCicatrixHumansNerve RegenerationReceptors, Cell SurfaceSpinal Cord InjuriesChondroitin ABC Lyasechondroitin sulfate proteoglycan receptor, humanChondroitin Sulfate ProteoglycansReceptors, Cell Surface

Identifiers

PMID22836147
PMCPMC5454774
OpenAlexW2056135134

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.